Intradermal recombinant hepatitis B vaccine for healthcare workers who fail to respond to intramuscular vaccine.
To study the humoral immune responses, safety, and tolerability of intradermal recombinant hepatitis B vaccination in healthcare workers (HCWs) nonresponsive to previous repeated intramuscular vaccination. An open, prospective, before-after trial. A tertiary referral hospital and surrounding district health service in Queensland, Australia. Hospital and community HCWs nonresponsive to previous intramuscular hepatitis B vaccination. Intradermal recombinant hepatitis B vaccine was administered every second week for a maximum of 4 doses. Hepatitis B surface antibody (anti-HBs) responses were assessed 2 weeks after each dose. Protective anti-HBs levels developed in 17 (94%) of 18 study subjects. Three doses resulted in seroconversion of all responding subjects and the highest geometric mean antibody concentration. The vaccine was well tolerated. More than 90% of previously nonresponsive HCWs responded to intradermal recombinant hepatitis B vaccine with protective anti-HBs levels.